Trial Profile
Safety and efficacy of switching of natalizumab to fingolimod in patients with relapsing remitting multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2015
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms SWITCH-UHBS
- 07 Dec 2015 Status changed from not stated to completed.
- 07 Dec 2015 New trial record